Drogas com maior potencial de uso na Esclerose Lateral Amiotrófica
DOI:
https://doi.org/10.34024/rnc.2006.v14.8771Palavras-chave:
SuplementoResumo
.
Referências
Gordon PH, Moore DH, Gelinas DF, Qualls C, Meister ME, Werner J, et al. Palcebo controlled phase I / II studies of minocycline in amyotrophic lateral sclerosis. Neurology 2004, 62: 1845-1847. DOI: https://doi.org/10.1212/01.WNL.0000125321.92112.7E
Pontieri FE, Ricci A, Pellicano C, Benincasa D, Buttarelli FR. Minocycline in amyotrophic lateral sclerosis: a pilot study. Neurol Sci 2005, 26: 285-287. DOI: https://doi.org/10.1007/s10072-005-0474-x
Quadros AJQ, Oliveira ASB, Silva HCA. ELA – Esclerose Lateral Amiotrófica - Atualização. Livreto informativo, Graf. RJR, São Paulo, 2006, p.22.
Muchowski PJ, Wacker JL. Modulation of neurodegeneration by molecular chaperones. Nat Rev Neurosci 2005, 6: 11-22. DOI: https://doi.org/10.1038/nrn1587
Kieran D, Kalmar B, Dick JR, Riddoch-Contreras J, Burnstock G, Greensmith L. Treatment with arimoclomol, a coinducer of heart chocks proteins, delay disease progression in ALS mice. Nat Med 2004, 10 (4): 345-407. DOI: https://doi.org/10.1038/nm1021
